Compounds > deferoxamine

deferoxamine and azacitidine

deferoxamine has been researched along with azacitidine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Beach, LB; Dapp, MJ; Heineman, RH; Mansky, LM; Martin, JL; Patterson, SE; Rawson, JM; Schnettler, EK1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH1

Reviews

1 review(s) available for deferoxamine and azacitidine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for deferoxamine and azacitidine

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.
    Bioorganic & medicinal chemistry, 2013, Nov-15, Volume: 21, Issue:22

    Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Inhibitors; Genes, Reporter; Green Fluorescent Proteins; HIV-1; Humans; Luminescent Proteins; Mutation; Red Fluorescent Protein; Resveratrol; Ribonucleotide Reductases; Stilbenes; Viral Proteins

2013
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:9

    Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States

2008